BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ananthakrishnan AN, Luo C, Yajnik V, Khalili H, Garber JJ, Stevens BW, Cleland T, Xavier RJ. Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. Cell Host Microbe 2017; 21: 603-610. e3. [PMID: 28494241 DOI: 10.1016/j.chom.2017.04.010] [Cited by in Crossref: 150] [Cited by in F6Publishing: 132] [Article Influence: 30.0] [Reference Citation Analysis]
Number Citing Articles
1 Person H, Keefer L. Psychological comorbidity in gastrointestinal diseases: Update on the brain-gut-microbiome axis. Prog Neuropsychopharmacol Biol Psychiatry. 2021;107:110209. [PMID: 33326819 DOI: 10.1016/j.pnpbp.2020.110209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Artacho A, Isaac S, Nayak R, Flor-Duro A, Alexander M, Koo I, Manasson J, Smith PB, Rosenthal P, Homsi Y, Gulko P, Pons J, Puchades-Carrasco L, Izmirly P, Patterson A, Abramson SB, Pineda-Lucena A, Turnbaugh PJ, Ubeda C, Scher JU. The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis. Arthritis Rheumatol 2021;73:931-42. [PMID: 33314800 DOI: 10.1002/art.41622] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
3 Kong L, Lloyd-Price J, Vatanen T, Seksik P, Beaugerie L, Simon T, Vlamakis H, Sokol H, Xavier RJ. Linking Strain Engraftment in Fecal Microbiota Transplantation With Maintenance of Remission in Crohn's Disease. Gastroenterology 2020;159:2193-2202.e5. [PMID: 32860788 DOI: 10.1053/j.gastro.2020.08.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
4 Zhou YH, Gallins P. A Review and Tutorial of Machine Learning Methods for Microbiome Host Trait Prediction.Front Genet. 2019;10:579. [PMID: 31293616 DOI: 10.3389/fgene.2019.00579] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 16.7] [Reference Citation Analysis]
5 Ankersen DV, Weimers P, Marker D, Johannesen T, Iversen S, Lilje B, Kristoffersen AB, Saboori S, Paridaens K, Skytt Andersen P, Burisch J, Munkholm P. eHealth: Disease activity measures are related to the faecal gut microbiota in adult patients with ulcerative colitis. Scand J Gastroenterol 2020;55:1291-300. [PMID: 33045169 DOI: 10.1080/00365521.2020.1829031] [Reference Citation Analysis]
6 Dovrolis N, Filidou E, Kolios G. Systems biology in inflammatory bowel diseases: on the way to precision medicine. Ann Gastroenterol 2019;32:233-46. [PMID: 31040620 DOI: 10.20524/aog.2019.0373] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Ding NS, McDonald JAK, Perdones-Montero A, Rees DN, Adegbola SO, Misra R, Hendy P, Penez L, Marchesi JR, Holmes E, Sarafian MH, Hart AL. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease. J Crohns Colitis 2020;14:1090-102. [PMID: 32119090 DOI: 10.1093/ecco-jcc/jjaa039] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
8 Lucafò M, Franzin M, Lagatolla C, Franca R, Bramuzzo M, Stocco G, Decorti G. Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients. Clin Transl Sci 2020;13:238-59. [PMID: 31675176 DOI: 10.1111/cts.12722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Effenberger M, Reider S, Waschina S, Bronowski C, Enrich B, Adolph TE, Koch R, Moschen AR, Rosenstiel P, Aden K, Tilg H. Microbial Butyrate Synthesis Indicates Therapeutic Efficacy of Azathioprine in IBD Patients. J Crohns Colitis 2021;15:88-98. [PMID: 32687146 DOI: 10.1093/ecco-jcc/jjaa152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
10 Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. J Allergy Clin Immunol. 2020;145:16-27. [PMID: 31910984 DOI: 10.1016/j.jaci.2019.11.003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 36.5] [Reference Citation Analysis]
11 Braga Neto MB, Gregory MH, Ramos GP, Bazerbachi F, Bruining DH, Abu Dayyeh BK, Kushnir VM, Raffals LE, Ciorba MA, Loftus EV, Deepak P. Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:1089-97. [PMID: 31613968 DOI: 10.1093/ibd/izz236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
12 Roosenboom B, Lochem EGV, Meijer J, Smids C, Nierkens S, Brand EC, Erp LWV, Kemperman LGJM, Groenen MJM, Horje CSHT, Wahab PJ. Development of Mucosal PNAd+ and MAdCAM-1+ Venules during Disease Course in Ulcerative Colitis. Cells 2020;9:E891. [PMID: 32268498 DOI: 10.3390/cells9040891] [Reference Citation Analysis]
13 Atreya R, Neurath MF. Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2018;3:790-802. [PMID: 30353856 DOI: 10.1016/S2468-1253(18)30265-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 8.3] [Reference Citation Analysis]
14 Zhao M, Bendtsen F, Petersen AM, Larsen L, Dige A, Hvas C, Seidelin JB, Burisch J. Predictors of response and disease course in patients with inflammatory bowel disease treated with biological therapy-the Danish IBD Biobank Project: protocol for a multicentre prospective cohort study. BMJ Open 2020;10:e035756. [PMID: 32102828 DOI: 10.1136/bmjopen-2019-035756] [Reference Citation Analysis]
15 Chapuis-Biron C, Bourrier A, Nachury M, Nancey S, Bouhnik Y, Serrero M, Armengol-Debeir L, Buisson A, Tran-Minh ML, Zallot C, Fumery M, Bouguen G, Abitbol V, Viennot S, Chanteloup E, Rajca S, Dib N, Parmentier AL, Peyrin-Biroulet L, Vuitton L;  GETAID BioLAP Study Group. Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients. Aliment Pharmacol Ther. 2020;51:719-727. [PMID: 32080886 DOI: 10.1111/apt.15665] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
16 He C, Wang H, Liao WD, Peng C, Shu X, Zhu X, Zhu ZH. Characteristics of mucosa-associated gut microbiota during treatment in Crohn’s disease. World J Gastroenterol 2019; 25(18): 2204-2216 [PMID: 31143071 DOI: 10.3748/wjg.v25.i18.2204] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
17 Hu JE, Weiß F, Bojarski C, Branchi F, Schulzke JD, Fromm M, Krug SM. Expression of tricellular tight junction proteins and the paracellular macromolecule barrier are recovered in remission of ulcerative colitis. BMC Gastroenterol 2021;21:141. [PMID: 33789594 DOI: 10.1186/s12876-021-01723-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Hyams JS, Davis Thomas S, Gotman N, Haberman Y, Karns R, Schirmer M, Mo A, Mack DR, Boyle B, Griffiths AM, LeLeiko NS, Sauer CG, Keljo DJ, Markowitz J, Baker SS, Rosh J, Baldassano RN, Patel A, Pfefferkorn M, Otley A, Heyman M, Noe J, Oliva-Hemker M, Rufo PA, Strople J, Ziring D, Guthery SL, Sudel B, Benkov K, Wali P, Moulton D, Evans J, Kappelman MD, Marquis MA, Sylvester FA, Collins MH, Venkateswaran S, Dubinsky M, Tangpricha V, Spada KL, Saul B, Wang J, Serrano J, Hommel K, Marigorta UM, Gibson G, Xavier RJ, Kugathasan S, Walters T, Denson LA. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. Lancet. 2019;393:1708-1720. [PMID: 30935734 DOI: 10.1016/s0140-6736(18)32592-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 17] [Article Influence: 15.7] [Reference Citation Analysis]
19 Verstockt B, Noor NM, Marigorta UM, Pavlidis P, Deepak P, Ungaro RC; Scientific Workshop Steering Committee . Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy. J Crohns Colitis 2021;15:1431-42. [PMID: 33730756 DOI: 10.1093/ecco-jcc/jjab050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Caenepeel C, Sadat Seyed Tabib N, Vieira-Silva S, Vermeire S. Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:1453-68. [PMID: 32969507 DOI: 10.1111/apt.16096] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
21 Soendergaard C, Seidelin JB, Steenholdt C, Nielsen OH. Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. BMJ Open Gastroenterol 2018;5:e000208. [PMID: 29915667 DOI: 10.1136/bmjgast-2018-000208] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
22 Yu D, Xia Y, Ge L, Tan B, Chen S. Effects of Lactococcus lactis on the Intestinal Functions in Weaning Piglets. Front Nutr 2021;8:713256. [PMID: 34490327 DOI: 10.3389/fnut.2021.713256] [Reference Citation Analysis]
23 Liu Y, Luo L, Luo Y, Zhang J, Wang X, Sun K, Zeng L. Prebiotic Properties of Green and Dark Tea Contribute to Protective Effects in Chemical-Induced Colitis in Mice: A Fecal Microbiota Transplantation Study. J Agric Food Chem 2020;68:6368-80. [PMID: 32419454 DOI: 10.1021/acs.jafc.0c02336] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
24 Meserve J, Dulai P. Predicting Response to Vedolizumab in Inflammatory Bowel Disease. Front Med (Lausanne) 2020;7:76. [PMID: 32300596 DOI: 10.3389/fmed.2020.00076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
25 Gubatan J, Keyashian K, Rubin SJS, Wang J, Buckman CA, Sinha S. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives. Clin Exp Gastroenterol 2021;14:333-42. [PMID: 34466013 DOI: 10.2147/CEG.S293272] [Reference Citation Analysis]
26 Ananthakrishnan AN. Microbiome-Based Biomarkers for IBD. Inflamm Bowel Dis 2020;26:1463-9. [PMID: 32311010 DOI: 10.1093/ibd/izaa071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Sharma A, Buschmann MM, Gilbert JA. Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response? Clin Pharmacol Ther 2019;106:317-28. [PMID: 30937887 DOI: 10.1002/cpt.1437] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
28 Zundler S, Becker E, Schulze LL, Neurath MF. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut 2019;68:1688-700. [DOI: 10.1136/gutjnl-2018-317977] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
29 Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020;14:694-709. [DOI: 10.1093/ecco-jcc/jjz195] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
30 Reens AL, Cabral DJ, Liang X, Norton JE Jr, Therien AG, Hazuda DJ, Swaminathan G. Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination. Front Immunol 2021;12:643255. [PMID: 34054810 DOI: 10.3389/fimmu.2021.643255] [Reference Citation Analysis]
31 Álvarez-Mercado AI, Navarro-Oliveros M, Robles-Sánchez C, Plaza-Díaz J, Sáez-Lara MJ, Muñoz-Quezada S, Fontana L, Abadía-Molina F. Microbial Population Changes and Their Relationship with Human Health and Disease. Microorganisms 2019;7:E68. [PMID: 30832423 DOI: 10.3390/microorganisms7030068] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
32 Yang XJ, Liu D, Ren HY, Zhang XY, Zhang J, Yang XJ. Effects of sepsis and its treatment measures on intestinal flora structure in critical care patients. World J Gastroenterol 2021; 27(19): 2376-2393 [PMID: 34040329 DOI: 10.3748/wjg.v27.i19.2376] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Vatn S, Carstens A, Kristoffersen AB, Bergemalm D, Casén C, Moen AEF, Tannaes TM, Lindstrøm J, Detlie TE, Olbjørn C, Lindquist CM, Söderholm JD, Gomollón F, Kalla R, Satsangi J, Vatn MH, Jahnsen J, Halfvarson J, Ricanek P; IBD-Character Consortium. Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character). Scand J Gastroenterol 2020;55:1146-56. [PMID: 32780604 DOI: 10.1080/00365521.2020.1803396] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Somineni HK, Weitzner JH, Venkateswaran S, Dodd A, Prince J, Karikaran A, Sauer CG, Abramowicz S, Zwick ME, Cutler DJ, Okou DT, Chopra P, Kugathasan S. Site- and Taxa-Specific Disease-Associated Oral Microbial Structures Distinguish Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021:izab082. [PMID: 34002220 DOI: 10.1093/ibd/izab082] [Reference Citation Analysis]
35 Lam KN, Alexander M, Turnbaugh PJ. Precision Medicine Goes Microscopic: Engineering the Microbiome to Improve Drug Outcomes. Cell Host Microbe 2019;26:22-34. [PMID: 31295421 DOI: 10.1016/j.chom.2019.06.011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 14.0] [Reference Citation Analysis]
36 Breidert M, Eftekhari P, Louis F, Rotoiu C, Rath T, Neurath MF, Atreya R. Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients. Crohns Colitis 360 2020;2:otaa037. [PMID: 32776006 DOI: 10.1093/crocol/otaa037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Sudun S, Liu S, Xiao C, Peng C, Liang L, He X, Zhao S, Zhang G. Probiotic strains improve high-fat diet-induced hypercholesterolemia through modulating gut microbiota in ways different from atorvastatin. Food Funct 2019;10:6098-109. [DOI: 10.1039/c9fo00444k] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Ribaldone DG, Caviglia GP, Abdulle A, Pellicano R, Ditto MC, Morino M, Fusaro E, Saracco GM, Bugianesi E, Astegiano M. Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease. J Clin Med 2019;8:E1646. [PMID: 31601034 DOI: 10.3390/jcm8101646] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
39 Imhann F, Van der Velde KJ, Barbieri R, Alberts R, Voskuil MD, Vich Vila A, Collij V, Spekhorst LM, Van der Sloot KWJ, Peters V, Van Dullemen HM, Visschedijk MC, Festen EAM, Swertz MA, Dijkstra G, Weersma RK. The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1. BMC Gastroenterol 2019;19:5. [PMID: 30621600 DOI: 10.1186/s12876-018-0917-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
40 Yang C, Peng C, Jin H, You L, Wang J, Xu H, Sun Z. Comparison of the composition and function of the gut microbiome in herdsmen from two pasture regions, Hongyuan and Xilingol. Food Sci Nutr 2021;9:3258-68. [PMID: 34136190 DOI: 10.1002/fsn3.2290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Qian G, Ho JWK. Challenges and emerging systems biology approaches to discover how the human gut microbiome impact host physiology. Biophys Rev 2020;12:851-63. [PMID: 32638331 DOI: 10.1007/s12551-020-00724-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
42 Somineni HK, Kugathasan S. The Microbiome in Patients With Inflammatory Diseases. Clin Gastroenterol Hepatol 2019;17:243-55. [PMID: 30196163 DOI: 10.1016/j.cgh.2018.08.078] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
43 Guo XY, Liu XJ, Hao JY. Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment. J Dig Dis. 2020;21:147-159. [PMID: 32040250 DOI: 10.1111/1751-2980.12849] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
44 Cao B, Zhang KC, Wei B, Chen L. Status quo and future prospects of artificial neural network from the perspective of gastroenterologists. World J Gastroenterol 2021; 27(21): 2681-2709 [PMID: 34135549 DOI: 10.3748/wjg.v27.i21.2681] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Takahashi MK, Tan X, Dy AJ, Braff D, Akana RT, Furuta Y, Donghia N, Ananthakrishnan A, Collins JJ. A low-cost paper-based synthetic biology platform for analyzing gut microbiota and host biomarkers. Nat Commun 2018;9:3347. [PMID: 30131493 DOI: 10.1038/s41467-018-05864-4] [Cited by in Crossref: 110] [Cited by in F6Publishing: 85] [Article Influence: 27.5] [Reference Citation Analysis]
46 Marafini I, Monteleone G. Precision Medicine in Inflammatory Bowel Diseases. Front Pharmacol 2021;12:653924. [PMID: 33927628 DOI: 10.3389/fphar.2021.653924] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Ruszkowski J, Daca A, Szewczyk A, Dębska-Ślizień A, Witkowski JM. The influence of biologics on the microbiome in immune-mediated inflammatory diseases: A systematic review. Biomed Pharmacother 2021;141:111904. [PMID: 34328113 DOI: 10.1016/j.biopha.2021.111904] [Reference Citation Analysis]
48 Barré A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther 2018;47:896-905. [PMID: 29430672 DOI: 10.1111/apt.14550] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 16.0] [Reference Citation Analysis]
49 Taguer M, Darbinian E, Wark K, Ter-Cheam A, Stephens DA, Maurice CF. Changes in Gut Bacterial Translation Occur before Symptom Onset and Dysbiosis in Dextran Sodium Sulfate-Induced Murine Colitis. mSystems 2021;6:e0050721. [PMID: 34874778 DOI: 10.1128/mSystems.00507-21] [Reference Citation Analysis]
50 Feng W, Liu J, Ao H, Yue S, Peng C. Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs. Theranostics 2020;10:11278-301. [PMID: 33042283 DOI: 10.7150/thno.47289] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
51 Morilla I, Uzzan M, Laharie D, Cazals-Hatem D, Denost Q, Daniel F, Belleannee G, Bouhnik Y, Wainrib G, Panis Y, Ogier-Denis E, Treton X. Colonic MicroRNA Profiles, Identified by a Deep Learning Algorithm, That Predict Responses to Therapy of Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019;17:905-913. [PMID: 30223112 DOI: 10.1016/j.cgh.2018.08.068] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
52 Ji Y, Fan X, Zhang Y, Li J, Dai Z, Wu Z. Glycine regulates mucosal immunity and the intestinal microbial composition in weaned piglets. Amino Acids 2021. [PMID: 33839961 DOI: 10.1007/s00726-021-02976-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Radhakrishnan ST, Alexander JL, Mullish BH, Gallagher KI, Powell N, Hicks LC, Hart AL, Li JV, Marchesi JR, Williams HRT. Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease. Aliment Pharmacol Ther 2021. [PMID: 34751954 DOI: 10.1111/apt.16656] [Reference Citation Analysis]
54 Siegel CA, Bernstein CN. Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complications. Clinical Gastroenterology and Hepatology 2020;18:1261-7. [DOI: 10.1016/j.cgh.2019.11.034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
55 Borg-Bartolo SP, Boyapati RK, Satsangi J, Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res. 2020;9. [PMID: 32047622 DOI: 10.12688/f1000research.20928.1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
56 Mo Q, Liu T, Fu A, Ruan S, Zhong H, Tang J, Zhao M, Li Y, Zhu S, Cai H, Feng F. Novel Gut Microbiota Patterns Involved in the Attenuation of Dextran Sodium Sulfate-Induced Mouse Colitis Mediated by Glycerol Monolaurate via Inducing Anti-inflammatory Responses. mBio 2021;12:e0214821. [PMID: 34634946 DOI: 10.1128/mBio.02148-21] [Reference Citation Analysis]
57 Turjeman S, Koren O. Using the microbiome in clinical practice. Microb Biotechnol 2022;15:129-34. [PMID: 34767683 DOI: 10.1111/1751-7915.13971] [Reference Citation Analysis]
58 Spencer EA, Dubinsky MC. Precision Medicine in Pediatric Inflammatory Bowel Disease. Pediatr Clin North Am 2021;68:1171-90. [PMID: 34736583 DOI: 10.1016/j.pcl.2021.07.011] [Reference Citation Analysis]
59 Knox NC, Forbes JD, Peterson CL, Van Domselaar G, Bernstein CN. The Gut Microbiome in Inflammatory Bowel Disease: Lessons Learned From Other Immune-Mediated Inflammatory Diseases. Am J Gastroenterol. 2019;114:1051-1070. [PMID: 31232832 DOI: 10.14309/ajg.0000000000000305] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
60 Peyrottes A, Seksik P, Doré J, Marteau P. The Microbiome in IBD. In: Sheng Ding N, De Cruz P, editors. Biomarkers in Inflammatory Bowel Diseases. Cham: Springer International Publishing; 2019. pp. 293-301. [DOI: 10.1007/978-3-030-11446-6_24] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
61 Schupack DA, Mars RAT, Voelker DH, Abeykoon JP, Kashyap PC. The promise of the gut microbiome as part of individualized treatment strategies. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34453142 DOI: 10.1038/s41575-021-00499-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Sullivan KE, Conrad M, Kelsen JR. Very early-onset inflammatory bowel disease: an integrated approach. Curr Opin Allergy Clin Immunol 2018;18:459-69. [PMID: 30299395 DOI: 10.1097/ACI.0000000000000484] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
63 Bolte LA, Klaassen MAY, Collij V, Vich Vila A, Fu J, van der Meulen TA, de Haan JJ, Versteegen GJ, Dotinga A, Zhernakova A, Wijmenga C, Weersma RK, Imhann F. Patient attitudes towards faecal sampling for gut microbiome studies and clinical care reveal positive engagement and room for improvement. PLoS One 2021;16:e0249405. [PMID: 33831035 DOI: 10.1371/journal.pone.0249405] [Reference Citation Analysis]
64 Gupta VK, Cunningham KY, Hur B, Bakshi U, Huang H, Warrington KJ, Taneja V, Myasoedova E, Davis JM 3rd, Sung J. Gut microbial determinants of clinically important improvement in patients with rheumatoid arthritis. Genome Med 2021;13:149. [PMID: 34517888 DOI: 10.1186/s13073-021-00957-0] [Reference Citation Analysis]
65 Sanchis-Artero L, Martínez-Blanch JF, Manresa-Vera S, Cortés-Castell E, Valls-Gandia M, Iborra M, Paredes-Arquiola JM, Boscá-Watts M, Huguet JM, Gil-Borrás R, Rodríguez-Morales J, Cortés-Rizo X. Evaluation of changes in intestinal microbiota in Crohn's disease patients after anti-TNF alpha treatment. Sci Rep 2021;11:10016. [PMID: 33976272 DOI: 10.1038/s41598-021-88823-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Zheng L, Wen XL. Gut microbiota and inflammatory bowel disease: The current status and perspectives. World J Clin Cases 2021; 9(2): 321-333 [PMID: 33521100 DOI: 10.12998/wjcc.v9.i2.321] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
67 Krautkramer KA, Dhillon RS, Denu JM, Carey HV. Metabolic programming of the epigenome: host and gut microbial metabolite interactions with host chromatin. Transl Res 2017;189:30-50. [PMID: 28919341 DOI: 10.1016/j.trsl.2017.08.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
68 Sharpton SR, Schnabl B, Knight R, Loomba R. Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. Cell Metab 2021;33:21-32. [PMID: 33296678 DOI: 10.1016/j.cmet.2020.11.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
69 Actis GC, Pellicano R, Fagoonee S, Ribaldone DG. History of Inflammatory Bowel Diseases. J Clin Med. 2019;8:1970. [PMID: 31739460 DOI: 10.3390/jcm8111970] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
70 Chu H. Host gene-microbiome interactions: molecular mechanisms in inflammatory bowel disease. Genome Med 2017;9:69. [PMID: 28738853 DOI: 10.1186/s13073-017-0459-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
71 Yu Y, Liu Q, Li H, Wen C, He Z. Alterations of the Gut Microbiome Associated With the Treatment of Hyperuricaemia in Male Rats. Front Microbiol 2018;9:2233. [PMID: 30283432 DOI: 10.3389/fmicb.2018.02233] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
72 Scherz V, Greub G, Bertelli C. Building up a clinical microbiota profiling: a quality framework proposal. Crit Rev Microbiol 2021;:1-20. [PMID: 34752719 DOI: 10.1080/1040841X.2021.1975642] [Reference Citation Analysis]
73 Miyoshi J, Maeda T, Matsuoka K, Saito D, Miyoshi S, Matsuura M, Okamoto S, Tamura S, Hisamatsu T. Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis. Sci Rep 2021;11:16440. [PMID: 34385588 DOI: 10.1038/s41598-021-96019-x] [Reference Citation Analysis]
74 Borren NZ, Conway G, Garber JJ, Khalili H, Budree S, Mallick H, Yajnik V, Xavier RJ, Ananthakrishnan AN. Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases. Journal of Crohn's and Colitis 2018;12:525-31. [DOI: 10.1093/ecco-jcc/jjx154] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
75 Metwaly A, Dunkel A, Waldschmitt N, Raj ACD, Lagkouvardos I, Corraliza AM, Mayorgas A, Martinez-Medina M, Reiter S, Schloter M, Hofmann T, Allez M, Panes J, Salas A, Haller D. Integrated microbiota and metabolite profiles link Crohn's disease to sulfur metabolism. Nat Commun 2020;11:4322. [PMID: 32859898 DOI: 10.1038/s41467-020-17956-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
76 Babbar A, Hitch TCA, Pabst O, Clavel T, Hübel J, Eswaran S, Wagner N, Schippers A. The Compromised Mucosal Immune System of β7 Integrin-Deficient Mice Has Only Minor Effects on the Fecal Microbiota in Homeostasis. Front Microbiol 2019;10:2284. [PMID: 31636620 DOI: 10.3389/fmicb.2019.02284] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
77 Cammarota G, Ianiro G, Ahern A, Carbone C, Temko A, Claesson MJ, Gasbarrini A, Tortora G. Gut microbiome, big data and machine learning to promote precision medicine for cancer. Nat Rev Gastroenterol Hepatol 2020;17:635-48. [DOI: 10.1038/s41575-020-0327-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
78 Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. Clin Gastroenterol Hepatol 2019;17:2497-2505.e1. [PMID: 30625408 DOI: 10.1016/j.cgh.2018.12.040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
79 Franzin M, Stefančič K, Lucafò M, Decorti G, Stocco G. Microbiota and Drug Response in Inflammatory Bowel Disease. Pathogens 2021;10:211. [PMID: 33669168 DOI: 10.3390/pathogens10020211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
80 Ananthakrishnan AN. Bugs and drugs: Predicting response to therapy. J Gastroenterol Hepatol 2018;33 Suppl 3:27. [PMID: 30187562 DOI: 10.1111/jgh.14432] [Reference Citation Analysis]
81 Plichta DR, Graham DB, Subramanian S, Xavier RJ. Therapeutic Opportunities in Inflammatory Bowel Disease: Mechanistic Dissection of Host-Microbiome Relationships. Cell. 2019;178:1041-1056. [PMID: 31442399 DOI: 10.1016/j.cell.2019.07.045] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 30.5] [Reference Citation Analysis]
82 Sorrentino D, Nguyen VQ, Chitnavis MV. Capturing the Biologic Onset of Inflammatory Bowel Diseases: Impact on Translational and Clinical Science. Cells 2019;8:E548. [PMID: 31174359 DOI: 10.3390/cells8060548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Honig G, Larkin PB, Heller C, Hurtado-Lorenzo A. Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:S1-S16. [PMID: 34791292 DOI: 10.1093/ibd/izab230] [Reference Citation Analysis]
84 Golob JL, Rao K. Signal Versus Noise: How to Analyze the Microbiome and Make Progress on Antimicrobial Resistance. J Infect Dis 2021;223:S214-21. [PMID: 33880565 DOI: 10.1093/infdis/jiab184] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Lang JM, Pan C, Cantor RM, Tang WHW, Garcia-Garcia JC, Kurtz I, Hazen SL, Bergeron N, Krauss RM, Lusis AJ. Impact of Individual Traits, Saturated Fat, and Protein Source on the Gut Microbiome. mBio 2018;9:e01604-18. [PMID: 30538180 DOI: 10.1128/mBio.01604-18] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 7.8] [Reference Citation Analysis]
86 Noor NM, Verstockt B, Parkes M, Lee JC. Personalised medicine in Crohn's disease. Lancet Gastroenterol Hepatol 2020;5:80-92. [PMID: 31818474 DOI: 10.1016/S2468-1253(19)30340-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 7.5] [Reference Citation Analysis]
87 Byrd AL, Liu M, Fujimura KE, Lyalina S, Nagarkar DR, Charbit B, Bergstedt J, Patin E, Harrison OJ, Quintana-Murci L, Mellman I, Duffy D, Albert ML; Milieu Intérieur Consortium. Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers. J Exp Med 2021;218:e20200606. [PMID: 33175106 DOI: 10.1084/jem.20200606] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
88 Scher JU, Nayak RR, Ubeda C, Turnbaugh PJ, Abramson SB. Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response. Nat Rev Rheumatol 2020;16:282-92. [PMID: 32157196 DOI: 10.1038/s41584-020-0395-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
89 Le Berre C, Sandborn WJ, Aridhi S, Devignes MD, Fournier L, Smaïl-Tabbone M, Danese S, Peyrin-Biroulet L. Application of Artificial Intelligence to Gastroenterology and Hepatology. Gastroenterology 2020;158:76-94.e2. [PMID: 31593701 DOI: 10.1053/j.gastro.2019.08.058] [Cited by in Crossref: 108] [Cited by in F6Publishing: 96] [Article Influence: 36.0] [Reference Citation Analysis]
90 Fan H, Hong X, Zeng J, Wang X, Chen J. Differences in the individual curative effect of acupuncture for obese women with polycystic ovary syndrome based on metagenomic analysis: study protocol for a randomized controlled trial. Trials 2021;22:454. [PMID: 34266458 DOI: 10.1186/s13063-021-05426-y] [Reference Citation Analysis]
91 Malham M, Lilje B, Houen G, Winther K, Andersen PS, Jakobsen C. The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease. Scand J Gastroenterol 2019;54:969-75. [PMID: 31329473 DOI: 10.1080/00365521.2019.1644368] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
92 Zhang R, Gao X, Bai H, Ning K. Traditional Chinese Medicine and Gut Microbiome: Their Respective and Concert Effects on Healthcare. Front Pharmacol 2020;11:538. [PMID: 32390855 DOI: 10.3389/fphar.2020.00538] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
93 Yoshimatsu Y, Mikami Y, Kanai T. Bacteriotherapy for inflammatory bowel disease. Inflamm Regen 2021;41:3. [PMID: 33441186 DOI: 10.1186/s41232-020-00153-4] [Reference Citation Analysis]
94 Salem F, Kindt N, Marchesi JR, Netter P, Lopez A, Kokten T, Danese S, Jouzeau JY, Peyrin-Biroulet L, Moulin D. Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences. United European Gastroenterol J 2019;7:1008-32. [PMID: 31662859 DOI: 10.1177/2050640619867555] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
95 Digby-Bell JL, Atreya R, Monteleone G, Powell N. Interrogating host immunity to predict treatment response in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020;17:9-20. [PMID: 31767987 DOI: 10.1038/s41575-019-0228-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
96 Buchner AM, Lichtenstein GR. Editorial: mesalazine and mucosal microbiome in quiescent ulcerative colitis-what can we learn? Aliment Pharmacol Ther 2019;49:1531. [PMID: 31134651 DOI: 10.1111/apt.15281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
97 Stange EF, Schroeder BO. Microbiota and mucosal defense in IBD: an update. Expert Rev Gastroenterol Hepatol. 2019;13:963-976. [PMID: 31603356 DOI: 10.1080/17474124.2019.1671822] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 11.7] [Reference Citation Analysis]
98 Stevens TW, Matheeuwsen M, Lönnkvist MH, Parker CE, Wildenberg ME, Gecse KB, D’haens GR. Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy. Aliment Pharmacol Ther 2018;48:1213-31. [DOI: 10.1111/apt.15033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
99 Schirbel A, Rebert N, Sadler T, West G, Rieder F, Wagener C, Horst A, Sturm A, de la Motte C, Fiocchi C. Mutual Regulation of TLR/NLR and CEACAM1 in the Intestinal Microvasculature: Implications for IBD Pathogenesis and Therapy. Inflamm Bowel Dis 2019;25:294-305. [PMID: 30295747 DOI: 10.1093/ibd/izy316] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
100 Schirmer M, Denson L, Vlamakis H, Franzosa EA, Thomas S, Gotman NM, Rufo P, Baker SS, Sauer C, Markowitz J, Pfefferkorn M, Oliva-Hemker M, Rosh J, Otley A, Boyle B, Mack D, Baldassano R, Keljo D, LeLeiko N, Heyman M, Griffiths A, Patel AS, Noe J, Kugathasan S, Walters T, Huttenhower C, Hyams J, Xavier RJ. Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. Cell Host Microbe 2018; 24: 600-610. e4. [PMID: 30308161 DOI: 10.1016/j.chom.2018.09.009] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 18.5] [Reference Citation Analysis]
101 Chen H, Li H, Liu Z. Interplay of intestinal microbiota and mucosal immunity in inflammatory bowel disease: a relationship of frenemies. Therap Adv Gastroenterol 2020;13:1756284820935188. [PMID: 32952611 DOI: 10.1177/1756284820935188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
102 Heshiki Y, Vazquez-Uribe R, Li J, Ni Y, Quainoo S, Imamovic L, Li J, Sørensen M, Chow BKC, Weiss GJ, Xu A, Sommer MOA, Panagiotou G. Predictable modulation of cancer treatment outcomes by the gut microbiota. Microbiome 2020;8:28. [PMID: 32138779 DOI: 10.1186/s40168-020-00811-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
103 Kowalska-Duplaga K, Kapusta P, Gosiewski T, Sroka-Oleksiak A, Ludwig-Słomczyńska AH, Wołkow PP, Fyderek K. Changes in the Intestinal Microbiota Are Seen Following Treatment with Infliximab in Children with Crohn's Disease. J Clin Med 2020;9:E687. [PMID: 32143438 DOI: 10.3390/jcm9030687] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
104 Neurath MF, Überla K, Ng SC. Gut as viral reservoir: lessons from gut viromes, HIV and COVID-19. Gut 2021;70:1605-8. [PMID: 33903146 DOI: 10.1136/gutjnl-2021-324622] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Collij V, Klaassen MAY, Weersma RK, Vila AV. Gut microbiota in inflammatory bowel diseases: moving from basic science to clinical applications. Hum Genet 2021;140:703-8. [PMID: 32857194 DOI: 10.1007/s00439-020-02218-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Verburgt CM, Ghiboub M, Benninga MA, de Jonge WJ, Van Limbergen JE. Nutritional Therapy Strategies in Pediatric Crohn's Disease. Nutrients 2021;13:212. [PMID: 33450982 DOI: 10.3390/nu13010212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Doestzada M, Vila AV, Zhernakova A, Koonen DPY, Weersma RK, Touw DJ, Kuipers F, Wijmenga C, Fu J. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell 2018;9:432-45. [PMID: 29705929 DOI: 10.1007/s13238-018-0547-2] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 14.0] [Reference Citation Analysis]
108 Flamant M, Roblin X. Inflammatory bowel disease: towards a personalized medicine. Therap Adv Gastroenterol 2018;11:1756283X17745029. [PMID: 29383027 DOI: 10.1177/1756283X17745029] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
109 Privitera G, Pugliese D, Rapaccini GL, Gasbarrini A, Armuzzi A, Guidi L. Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. J Clin Med 2021;10:853. [PMID: 33669579 DOI: 10.3390/jcm10040853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Doherty MK, Ding T, Koumpouras C, Telesco SE, Monast C, Das A, Brodmerkel C, Schloss PD. Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients. mBio 2018;9:e02120-17. [PMID: 29535202 DOI: 10.1128/mBio.02120-17] [Cited by in Crossref: 51] [Cited by in F6Publishing: 26] [Article Influence: 12.8] [Reference Citation Analysis]
111 Lee JWJ, Plichta D, Hogstrom L, Borren NZ, Lau H, Gregory SM, Tan W, Khalili H, Clish C, Vlamakis H, Xavier RJ, Ananthakrishnan AN. Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell Host Microbe 2021;29:1294-1304.e4. [PMID: 34297922 DOI: 10.1016/j.chom.2021.06.019] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
112 Mühl L, Becker E, Müller TM, Atreya R, Atreya I, Neurath MF, Zundler S. Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. BMC Gastroenterol 2021;21:33. [PMID: 33482730 DOI: 10.1186/s12876-021-01604-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
113 Paramsothy S, Kaakoush NO. Reply. Gastroenterology 2019;157:1165-6. [DOI: 10.1053/j.gastro.2019.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol 2018;11:1558-70. [PMID: 29907872 DOI: 10.1038/s41385-018-0050-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
115 Mallick H, Ma S, Franzosa EA, Vatanen T, Morgan XC, Huttenhower C. Experimental design and quantitative analysis of microbial community multiomics. Genome Biol 2017;18:228. [PMID: 29187204 DOI: 10.1186/s13059-017-1359-z] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 15.8] [Reference Citation Analysis]
116 Wang X, Xiao Y, Xu X, Guo L, Yu Y, Li N, Xu C. Characteristics of Fecal Microbiota and Machine Learning Strategy for Fecal Invasive Biomarkers in Pediatric Inflammatory Bowel Disease. Front Cell Infect Microbiol 2021;11:711884. [PMID: 34950604 DOI: 10.3389/fcimb.2021.711884] [Reference Citation Analysis]
117 Bekkers M, Stojkovic B, Kaiko GE. Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease. Int J Mol Sci 2021;22:11243. [PMID: 34681902 DOI: 10.3390/ijms222011243] [Reference Citation Analysis]
118 Estevinho MM, Rocha C, Correia L, Lago P, Ministro P, Portela F, Trindade E, Afonso J, Peyrin-Biroulet L, Magro F; GEDII (Portuguese IBD Group). Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: A Systematic Review. Clin Gastroenterol Hepatol 2020;18:1054-69. [PMID: 31526845 DOI: 10.1016/j.cgh.2019.08.063] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
119 Sprockett D, Fischer N, Boneh RS, Turner D, Kierkus J, Sladek M, Escher JC, Wine E, Yerushalmi B, Dias JA, Shaoul R, Kori M, Snapper SB, Holmes S, Bousvaros A, Levine A, Relman DA. Treatment-Specific Composition of the Gut Microbiota Is Associated With Disease Remission in a Pediatric Crohn's Disease Cohort. Inflamm Bowel Dis 2019;25:1927-38. [PMID: 31276165 DOI: 10.1093/ibd/izz130] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
120 Mahajna H, Ben-Horin S. Novel bio-genetic predictors of response to biologic treatment in inflammatory bowel diseases. Curr Opin Pharmacol 2020;55:132-40. [PMID: 33249396 DOI: 10.1016/j.coph.2020.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
121 Borren NZ, Plichta D, Joshi AD, Bonilla G, Sadreyev R, Vlamakis H, Xavier RJ, Ananthakrishnan AN. Multi-"-Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. Inflamm Bowel Dis 2020;26:1524-32. [PMID: 32766830 DOI: 10.1093/ibd/izaa183] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
122 Ghaly S, Hart PH, Lawrance IC. Inflammatory bowel diseases: interrelationships between dietary vitamin D, exposure to UV radiation and the fecal microbiome. Expert Rev Gastroenterol Hepatol 2019;13:1039-48. [PMID: 31657973 DOI: 10.1080/17474124.2019.1685874] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
123 Ahmed M, Metwaly A, Haller D. Modeling microbe-host interaction in the pathogenesis of Crohn's disease. Int J Med Microbiol 2021;311:151489. [PMID: 33676240 DOI: 10.1016/j.ijmm.2021.151489] [Reference Citation Analysis]
124 Liu Y, Wang Y, Ni Y, Cheung CK, Lam KS, Wang Y, Xia Z, Ye D, Guo J, Tse MA, Panagiotou G, Xu A. Gut Microbiome Fermentation Determines the Efficacy of Exercise for Diabetes Prevention. Cell Metabolism 2020;31:77-91.e5. [DOI: 10.1016/j.cmet.2019.11.001] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 31.5] [Reference Citation Analysis]
125 Utay NS, Somasunderam A, Hinkle JE, Petschow BW, Detzel CJ, Somsouk M, Fichtenbaum CJ, Weaver EM, Shaw AL, Asmuth DM. Serum Bovine Immunoglobulins Improve Inflammation and Gut Barrier Function in Persons with HIV and Enteropathy on Suppressive ART. Pathog Immun 2019;4:124-46. [PMID: 31139758 DOI: 10.20411/pai.v4i1.276] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
126 Hedin CR, McCarthy NE, Louis P, Farquharson FM, McCartney S, Stagg AJ, Lindsay JO, Whelan K. Prebiotic fructans have greater impact on luminal microbiology and CD3+ T cells in healthy siblings than patients with Crohn's disease: A pilot study investigating the potential for primary prevention of inflammatory bowel disease. Clin Nutr 2021;40:5009-19. [PMID: 34364241 DOI: 10.1016/j.clnu.2021.05.033] [Reference Citation Analysis]
127 Sharma D, Paterson AD, Xu W. TaxoNN: ensemble of neural networks on stratified microbiome data for disease prediction. Bioinformatics 2020;36:4544-50. [PMID: 32449747 DOI: 10.1093/bioinformatics/btaa542] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
128 Schirmer M, Garner A, Vlamakis H, Xavier RJ. Microbial genes and pathways in inflammatory bowel disease. Nat Rev Microbiol. 2019;17:497-511. [PMID: 31249397 DOI: 10.1038/s41579-019-0213-6] [Cited by in Crossref: 129] [Cited by in F6Publishing: 113] [Article Influence: 64.5] [Reference Citation Analysis]
129 Yau YY, Wasinger VC, Hirten RP, Chuang E, Huntsman M, Stylli J, Shimizu J, Yajnik V, Smith J, Lee SN, Singh S, Wahl C, Leong RW, Sands BE. Current Trends in IBD-Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System. Inflamm Bowel Dis 2021;27:S17-24. [PMID: 34791290 DOI: 10.1093/ibd/izab179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Alexander T, Snowden JA, Burman J, Chang HD, Del Papa N, Farge D, Lindsay JO, Malard F, Muraro PA, Nitti R, Salas A, Sharrack B, Mohty M, Greco R. Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases: Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT. Front Oncol 2021;11:722436. [PMID: 34745944 DOI: 10.3389/fonc.2021.722436] [Reference Citation Analysis]
131 Danese S. New Drugs in the Ulcerative Colitis Pipeline: Prometheus Unbound. Gastroenterology 2020;158:467-70. [PMID: 31862200 DOI: 10.1053/j.gastro.2019.12.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
132 Jiang P, Lai S, Wu S, Zhao XM, Chen WH. Host DNA contents in fecal metagenomics as a biomarker for intestinal diseases and effective treatment. BMC Genomics 2020;21:348. [PMID: 32393180 DOI: 10.1186/s12864-020-6749-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
133 Allner C, Melde M, Becker E, Fuchs F, Mühl L, Klenske E, Müller L, Morgenstern N, Fietkau K, Hirschmann S, Atreya R, Atreya I, Neurath MF, Zundler S. Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study. BMC Gastroenterol 2020;20:103. [PMID: 32293299 DOI: 10.1186/s12876-020-01253-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
134 Wolter M, Grant ET, Boudaud M, Steimle A, Pereira GV, Martens EC, Desai MS. Leveraging diet to engineer the gut microbiome. Nat Rev Gastroenterol Hepatol 2021;18:885-902. [PMID: 34580480 DOI: 10.1038/s41575-021-00512-7] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
135 Pagnini C, Pizarro TT, Cominelli F. Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor. Front Pharmacol. 2019;10:671. [PMID: 31316377 DOI: 10.3389/fphar.2019.00671] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
136 Burrello C, Garavaglia F, Cribiù FM, Ercoli G, Lopez G, Troisi J, Colucci A, Guglietta S, Carloni S, Guglielmetti S, Taverniti V, Nizzoli G, Bosari S, Caprioli F, Rescigno M, Facciotti F. Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells. Nat Commun 2018;9:5184. [PMID: 30518790 DOI: 10.1038/s41467-018-07359-8] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 17.3] [Reference Citation Analysis]
137 Knox NC, Forbes JD, Van Domselaar G, Bernstein CN. The Gut Microbiome as a Target for IBD Treatment: Are We There Yet? Curr Treat Options Gastro 2019;17:115-26. [DOI: 10.1007/s11938-019-00221-w] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 15.7] [Reference Citation Analysis]
138 Wyatt NJ, Speight RA, Stewart CJ, Kirby JA, Lamb CA. Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. BioDrugs 2021;35:473-503. [PMID: 34613592 DOI: 10.1007/s40259-021-00496-5] [Reference Citation Analysis]
139 Wu N, Mah C, Koentgen S, Zhang L, Grimm MC, El-Omar E, Hold GL. Inflammatory bowel disease and the gut microbiota. Proc Nutr Soc 2021;:1-11. [PMID: 34165053 DOI: 10.1017/S002966512100197X] [Reference Citation Analysis]
140 Majchrzak K, Fichna J. Biologic Therapy in Crohn's Disease-What We Have Learnt So Far. Curr Drug Targets 2020;21:792-806. [PMID: 31854272 DOI: 10.2174/1389450121666191218123203] [Reference Citation Analysis]
141 Gershuni V, Li Y, Elovitz M, Li H, Wu GD, Compher CW. Maternal gut microbiota reflecting poor diet quality is associated with spontaneous preterm birth in a prospective cohort study. Am J Clin Nutr 2021;113:602-11. [PMID: 33515003 DOI: 10.1093/ajcn/nqaa361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
142 Curini L, Amedei A. Cardiovascular Diseases and Pharmacomicrobiomics: A Perspective on Possible Treatment Relevance. Biomedicines 2021;9:1338. [PMID: 34680455 DOI: 10.3390/biomedicines9101338] [Reference Citation Analysis]
143 D'Adamo GL, Widdop JT, Giles EM. The future is now? Clinical and translational aspects of "Omics" technologies. Immunol Cell Biol 2021;99:168-76. [PMID: 32924178 DOI: 10.1111/imcb.12404] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
144 Chowers Y. One Size Does Not Fit All: The Case for Translational Medicine. Rambam Maimonides Med J 2019;10. [PMID: 30860477 DOI: 10.5041/RMMJ.10364] [Reference Citation Analysis]
145 Dalal RS, Ananthakrishnan AN, Hamilton MJ, Winter RW. Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab. Dig Dis Sci 2021;66:733-7. [PMID: 33569666 DOI: 10.1007/s10620-021-06852-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Volkova A, Ruggles KV. Predictive Metagenomic Analysis of Autoimmune Disease Identifies Robust Autoimmunity and Disease Specific Microbial Signatures. Front Microbiol 2021;12:621310. [PMID: 33746917 DOI: 10.3389/fmicb.2021.621310] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]